News Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at PNS 2022

News Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at PNS 2022

New results from the HELIOS-A study of vutrisiran, an investigational RNAi therapeutic, in hereditary transthyretin-mediated (hATTR) amyloidosis patients with polyneuropathy, were presented during the Peripheral Nerve Society (PNS) 2022 Annual Meeting, taking place May 14-17, 2022.

Ajroud-Driss, et al. “HELIOS-A: Impact of Vutrisiran on Quality of Life and Functional Status in Hereditary Transthyretin-Mediated Amyloidosis”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.